Clinical Trial Update: TAS-102 in Patients With Advanced, Refractory Pancreatic Adenocarcinoma [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update from The University of Hong Kong evaluating TAS-102 in advanced, refractory pancreatic adenocarcinoma; the study has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Cancer

Drugs mentioned

• TAS-102 (trifluridine/tipiracil)

Snippet

Sponsor: The University of Hong Kong | Conditions: Pancreas Cancer | Phase 2 | Status: COMPLETED